Novo Nordisk reported 18.85B in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
Bausch Health Companies USD 894M 27M Jun/2025
Bristol-Myers Squibb USD 1.71B 129M Jun/2025
Eli Lilly USD 2.75B 390.8M Jun/2025
GlaxoSmithKline GBP 2.14B 80M Jun/2025
Merck USD 2.63B 104M Jun/2025
Novartis USD 3.44B 384M Jun/2025
Novo Nordisk 18.85B 2.74B Jun/2025
Novo Nordisk DKK 16.11B 480M Mar/2025
Pacira USD 77.19M 9.58M Jun/2025
Sanofi EUR 2.63B 408M Jun/2025
Supernus Pharmaceuticals USD 62.22M 27.72M Jun/2025